WO2018056528A3 - 인플루엔자 b 백신 - Google Patents

인플루엔자 b 백신 Download PDF

Info

Publication number
WO2018056528A3
WO2018056528A3 PCT/KR2017/000662 KR2017000662W WO2018056528A3 WO 2018056528 A3 WO2018056528 A3 WO 2018056528A3 KR 2017000662 W KR2017000662 W KR 2017000662W WO 2018056528 A3 WO2018056528 A3 WO 2018056528A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza
virus
yamagata
lineage
viruses
Prior art date
Application number
PCT/KR2017/000662
Other languages
English (en)
French (fr)
Other versions
WO2018056528A2 (ko
Inventor
장준
강정옥
Original Assignee
이화여자대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이화여자대학교 산학협력단 filed Critical 이화여자대학교 산학협력단
Publication of WO2018056528A2 publication Critical patent/WO2018056528A2/ko
Publication of WO2018056528A3 publication Critical patent/WO2018056528A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 인플루엔자 B 바이러스 중 B/Yamagata 계열 바이러스의 핵단백질을 코딩하는 유전자를 포함하고, 감염된 개체에서 인플루엔자 B 바이러스인 B/Yamagata 계열 바이러스 및 B/Victoria 계열 바이러스에 대한 면역성을 동시에 유도할 수 있는 재조합 아데노바이러스, 상기 재조합 아데노바이러스 또는 그의 바이러스 입자를 유효성분으로 포함하는 인플루엔자 B형 백신조성물 및 상기 인플루엔자 B 백신조성물을 이용하여 인플루엔자 B 바이러스의 감염으로 인한 질환을 예방 또는 치료하는 방법에 관한 것이다. 본 발명에서 제공하는 재조합 아데노바이러스는 B/Yamagata 계열 바이러스의 핵단백질을 코딩하는 유전자만을 포함하고 있음에도 불구하고, B/Yamagata 계열 바이러스는 물론 B/Victoria 계열 바이러스의 감염에 대하여도 면역성을 유도할 수 있으므로, 상기 재조합 아데노바이러스는 인플루엔자 B 바이러스에 대한 범용적인 백신으로 사용되어, 인플루엔자 B 바이러스의 감염에 의하여 발병되는 다양한 질환의 예방 및 치료에 널리 활용될 수 있을 것이다.
PCT/KR2017/000662 2016-09-22 2017-01-19 인플루엔자 b 백신 WO2018056528A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160121556A KR101888751B1 (ko) 2016-09-22 2016-09-22 인플루엔자 b 백신
KR10-2016-0121556 2016-09-22

Publications (2)

Publication Number Publication Date
WO2018056528A2 WO2018056528A2 (ko) 2018-03-29
WO2018056528A3 true WO2018056528A3 (ko) 2018-08-02

Family

ID=61691021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/000662 WO2018056528A2 (ko) 2016-09-22 2017-01-19 인플루엔자 b 백신

Country Status (2)

Country Link
KR (1) KR101888751B1 (ko)
WO (1) WO2018056528A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116144612B (zh) * 2022-12-08 2023-11-10 广州医科大学附属第一医院（广州呼吸中心） 重组乙型流感病毒及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080100441A (ko) * 2006-02-07 2008-11-18 펩트셀 리미티드 펩타이드 서열 및 조성물
KR20090034297A (ko) * 2006-02-16 2009-04-07 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 인플루엔자에 대한 항바이러스제 및 백신

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080100441A (ko) * 2006-02-07 2008-11-18 펩트셀 리미티드 펩타이드 서열 및 조성물
KR20090034297A (ko) * 2006-02-16 2009-04-07 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 인플루엔자에 대한 항바이러스제 및 백신

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "The Study on Cholera Toxin-Mediated Th17 Cell Differentiation and Universal Influenza B Vaccine", PH.D. THESIS, 2016, pages i-viiii, 1 - 101, XP055531820 *
DATABASE Protein [O] 29 December 2006 (2006-12-29), "nucleoprotein [Influenza B virus (B/Yamagata/16/1988)]", XP 055528484, Database accession no. ABL77260.1 *
KIM, SO-HEE ET AL.: "Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection", PLOS ONE, vol. 8, no. 9, 25 September 2013 (2013-09-25), pages 1 - 11, XP 055528470 *
VAN DE SANDT, CAROLIEN E. ET AL.: "Influenza B Virus-specific CD 8+ T-lympho-cytes Strongly Cross-react with Viruses of the Opposing Influenza B Lineage", JOURNAL OF GENERAL VIROLOGY, vol. 96, no. 8, August 2015 (2015-08-01), pages 2061 - 2073, XP 055528477 *

Also Published As

Publication number Publication date
KR101888751B1 (ko) 2018-09-21
KR20180032721A (ko) 2018-04-02
WO2018056528A2 (ko) 2018-03-29

Similar Documents

Publication Publication Date Title
WO2017191258A9 (en) Influenza mrna vaccines
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
WO2016100807A3 (en) Human antibodies to influenza hemagglutinin
WO2017070620A3 (en) Broad spectrum influenza virus vaccine
MY201105A (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
PH12015502230A1 (en) Novel viral replication inhibitors
WO2017078577A3 (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
BR112015017966A2 (pt) composições imunogênicas compreendendo vírus silificado e métodos de uso
WO2015039010A3 (en) Deoxynojirimycin derivatives and methods of their using
PH12019550039A1 (en) Dihydropyrimidine compound and preparation method and use thereof
MX354676B (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
WO2020035609A3 (en) Immunogenic compositions and uses thereof
MX2019004029A (es) Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
MX2016002903A (es) Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
WO2016195522A3 (en) Antiviral composition
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
WO2018056528A3 (ko) 인플루엔자 b 백신
MY184269A (en) Broad-spectrum anti-influenza virus therapeutic peptides
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
WO2009152519A3 (en) Novel antiviral peptides against influenza virus
PH12017501943B1 (en) Influenza virus neutralizing peptidomimetic compounds
MX2014001158A (es) Virus recombinantes de influenza porcina y usos del mismo.
EA201792083A1 (ru) Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
WO2017031401A3 (en) Ns1 truncated virus for the development of canine influenza vaccines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17853242

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17853242

Country of ref document: EP

Kind code of ref document: A2